MedTrace Logo

MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

NCT05114213 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-12-05

No results posted yet for this study

Summary

The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients with metastatic PDAC (mPDAC).

Conditions

Interventions

RADIATION

SBRT

online adaptive MR-guided hypofractionated stereotactic radiotherapy

DRUG

SOC chemotherapy

The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.

Sponsors & Collaborators

  • Heidelberg University

    collaborator OTHER

  • University of Zurich

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Maximilian Niyazi, Prof. Dr. · Depatment of Radiation Oncology, University Hospital, LMU Munich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2025-11-11
Completion
2025-11-11

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05114213 on ClinicalTrials.gov